Drug
Lanadelumab clinical trials
Also written DX-2930, SHP643 and TAKHZYRO.
- studies test it
- 20
- open now
- 1
- in phase 3
- 9
- first study started
- 2013
Keep track of what changes. Save the lanadelumab studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
20 studies that test it; most in 2020 (6)
| Year | Studies |
|---|---|
| 2013 | 1 |
| 2014 | 1 |
| 2016 | 2 |
| 2018 | 1 |
| 2019 | 3 |
| 2020 | 6 |
| 2021 | 3 |
| 2022 | 2 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 8
- Phase 2
- 3
- Phase 3
- 9
- Phase 4
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 15 · Other 5
Shire (10) · Takeda (4) · St Vincent's Institute of Medical Research (1) · Charite University, Berlin, Germany (1) · Vanderbilt University Medical Center (1) · Amgen (1) · Radboud University Medical Center (1) · Bernstein Clinical Research Center (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses lanadelumab is read from its arms, and is right about nine times in ten.
Testing it · 20
- Lanadelumab in Long-term Prophylaxis of Acquired AngioedemaRecruitingPhase 4Bernstein Clinical Research CenterNCT06818474Written as Lanadelumab 300 mg
- Hemodialysis.-Induced Hypotension Therapy for End Stage Kidney DiseaseCompletedPhase 2Vanderbilt University Medical CenterNCT05297786Written as Lanadelumab Injection [Takhzyro]
- A Study of Lanadelumab (SHP643) in Chinese Participants With Hereditary Angioedema (HAE)CompletedPhase 3TakedaNCT05460325Written as Lanadelumab
- A Study of Long-Term Safety and Efficacy of Lanadelumab for Prevention of Acute Attacks of Non-histaminergic Angioedema With Normal C1-InhibitorCompletedPhase 3ShireNCT04444895Written as Lanadelumab
- Inhibition of Plasma Kallikrein as a New Therapy for Lung InjuryActive, not recruitingPhase 1St Vincent's Institute of Medical ResearchNCT04848272Written as Lanadelumab
- Lanadelumab in FXII-associated Cold Autoinflammatory Syndrome (FACAS)Active, not recruitingPhase 2Charite University, Berlin, GermanyNCT04278885Written as Lanadelumab
- A Study of Lanadelumab in Teenagers and Adults to Prevent Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH)CompletedPhase 3TakedaNCT04206605Written as Lanadelumab
- Expanded Access Program With Lanadelumab for Japanese People With Hereditary AngioedemaCompletedPhase 3TakedaNCT04687137Written as TAK-743 300 mg
- Efficacy and Safety of Lanadelumab (SHP643) in Japanese Participants With Hereditary Angioedema (HAE)CompletedPhase 3ShireNCT04180163Written as Lanadelumab
- Study of Multiple Candidate Agents for the Treatment of COVID-19 in Hospitalized PatientsCompletedPhase 3AmgenNCT04590586Written as Lanadelumab
- A Study of Lanadelumab to Prevent Hereditary Angioedema (HAE) Attacks in ChildrenCompletedPhase 3ShireNCT04070326Written as Lanadelumab
- A Study to Determine the Safety, Tolerability, and Pharmacokinetics of Lanadelumab Administered Intravenously in Healthy Adult Volunteer ParticipantsCompletedPhase 1TakedaNCT04503603Written as Lanadelumab
- Lanadelumab for Treatment of COVID-19 DiseaseCompletedPhase 1/2Radboud University Medical CenterNCT04422509Written as lanadelumab
- Long-term Safety and Efficacy Study of DX-2930 (SHP643) to Prevent Acute Angioedema Attacks in Patients With Type I and Type II HAECompletedPhase 3ShireNCT02741596Written as DX-2930
- Study of Lanadelumab in Healthy Japanese and Matched Caucasian Adult SubjectsCompletedPhase 1ShireNCT03401671Written as Lanadelumab
- Efficacy and Safety Study of DX-2930 to Prevent Acute Angioedema Attacks in Patients With Type I and Type II HAECompletedPhase 3ShireNCT02586805Written as DX-2930 - 300mg/2wk
- A Double-Blind, Multiple Ascending Dose Study to Assess Safety, Tolerability and Pharmacokinetics of DX-2930 in Hereditary Angioedema ParticipantsCompletedPhase 1ShireNCT02093923Written as DX-2930
- A Single Increasing Dose Study to Assess Safety and Tolerability of DX-2930 in Healthy SubjectsCompletedPhase 1ShireNCT01923207Written as DX-2930
- A Study to Determine the Bioavailability of Lanadelumab (SHP643) Administered Subcutaneously With the Prefilled Syringe and the Autoinjector in Healthy Adult Volunteer Participants.CompletedPhase 1ShireNCT03918239Written as SHP643
- Lanadelumab in Participants Hospitalized With COVID-19 PneumoniaWithdrawnPhase 1ShireNCT04460105Written as Lanadelumab
Codes
What other systems call lanadelumab · ClinicalTrials.gg INT000200
- MeSH (NLM) C000596550lanadelumabOne source NLM
- UNII (FDA) 2372V1TKXKLANADELUMABConfirmed FDA, NLM, Wikidata
- RxNorm 2055641Confirmed FDA, Wikidata
- Wikidata Q25326708lanadelumabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C166535LanadelumabOne source FDA
- DrugBank DB14597One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000596550 | lanadelumab | One source NLM |
| UNII (FDA) | 2372V1TKXK | LANADELUMAB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2055641 | — | Confirmed FDA, Wikidata |
| Wikidata | Q25326708 | lanadelumab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C166535 | Lanadelumab | One source FDA |
| DrugBank | DB14597 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.